CMS Rejects Medicare Payment for Genetic-Based Warfarin Dosing | GenomeWeb

NEW YORK (GenomeWeb News) – The Centers for Medicare and Medicaid Services said this week that it would not pay for genetic tests to help guide warfarin dosing for Medicare recipients, noting in a proposed decision memo that "available evidence does not demonstrate that pharmacogenomic testing to predict warfarin responsiveness improves health outcomes in Medicare beneficiaries."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.